flibanserin

Flibanserin, a compound identified as BIMT-17, acts as a complete agonist at the serotonin 5-HT1A receptor, with a binding affinity (Ki) of 1 nM, while functioning as an antagonist at the 5-HT2A receptor with a 49 nM affinity. Flibanserin D4 represents a deuterium-labeled version of Flibanserin.

Flibanserin-d4-1 is the deuterated form of Flibanserin. Flibanserin (BIMT-17) functions as a full agonist at the 5-hydroxytryptamine (5-HT1A) receptor with a Ki of 1 nM, and as an antagonist at the 5-HT2A receptor with a Ki of 49 nM. It binds to dopamine D4 receptors with an affinity ranging from 4 to 24 nM, while showing negligible affinity for various other neurotransmitter receptors and ion channels. Flibanserin is being investigated for its potential in treating hypoactive sexual desire disorder (HSDD).